ExpressionEdits optimizes protein expression by using AI and proprietary intronization technology that strategically incorporates short noncoding introns into synthetic genes. Its Genetic Syntax Engine integrates millions of biological data points with machine learning to predict and redesign genes across therapeutic modalities. The company was founded in 2021 based on University of Cambridge research by Dr. Kärt Tomberg, Professor Allan Bradley, and Dr. Liliana Antunes and is headquartered in Cambridge, UK. ExpressionEdits announced a $13 million seed round to accelerate candidate selection for preclinical studies and to develop a pipeline of protein-based therapeutics. The primary pipeline focus is on recombinant proteins that have historically faced production and manufacturing challenges. The platform aims to enable lower doses, reduce toxicity, expand tissue targeting, and unlock production of previously elusive therapeutic proteins to make protein therapeutics more accessible.

Total raised

$13M

Funding rounds

1

Latest round

Seed

Latest activity

May 2024